A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species.

Abstract:

:Manipulation of binding affinity between monoclonal antibodies (mAbs) and the neonatal Fc receptor (FcRn) has been leveraged to extend mAb half-life; however, the steps required for success remain ambiguous and experimental observations are inconsistent. Recent models have considered the time course of endosomal transit a major contributor to the relationship between FcRn affinity and antibody half-life. Our objective was to develop a minimal physiologically based pharmacokinetic model to explain how changes in IgG-FcRn association rate constant (Kon), dissociation rate constant (Koff), and endosomal transit time [T(w)] translate to improved IgG clearance across mice, monkeys and humans. By simulating mAb clearance across physiological values of Kon, Koff, and T(w), we found that lowering Koff improves clearance only until the dissociation half-life reaches endosomal transit time. In contrast, Kon influenced clearance independently of T(w).The model was then applied to fit 66 mAb plasma profiles across species digitized from the literature, and clearance of mAb (CLIgG) and vascular fluid-phase endocytosis rate (CLup) were estimated. We found that CLIgG scaled well with body weight (allometric exponent of 0.90). After accounting for mAbs with significant FcRn binding at physiological pH, CLup was allometrically scalable (exponent 0.72). For the antibodies surveyed, Kon was more highly correlated with CLIgG across all species. The relationship between Koff and KD with CLIgG was largely inconsistent. Taken together, this model provides a parsimonious approach to evaluate endosomal transit kinetics using only mAb plasma concentrations. These findings reinforce the idea that endosomal transit kinetics should be considered when modeling FcRn salvage.

journal_name

MAbs

journal_title

mAbs

authors

Maas BM,Cao Y

doi

10.1080/19420862.2018.1506648

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

1322-1331

issue

8

eissn

1942-0862

issn

1942-0870

journal_volume

10

pub_type

杂志文章

相关文献

mAbs文献大全
  • The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen.

    abstract::A dual-specific, tetravalent immunoglobulin G-like molecule, termed dual variable domain immunoglobulin (DVD-Ig™), is engineered to block two targets. Flexibility modulates Fc receptor and complement binding, but could result in undesirable cross-linking of surface antigens and downstream signaling. Understanding the ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.24258

    authors: Correia I,Sung J,Burton R,Jakob CG,Carragher B,Ghayur T,Radziejewski C

    更新日期:2013-05-01 00:00:00

  • Molecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individual.

    abstract::The cervical mucosa of women who are highly exposed to HIV-1, yet remain persistently seronegative (HEPS), presents a unique opportunity to study the dynamics of an immune compartment potentially capable of preventing HIV-1 infection. Herein, we provide a detailed characterization of the immunoglobulin repertoire of c...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.2.14858

    authors: Gaudet RG,Breden F,Plummer F,Berry JD

    更新日期:2011-03-01 00:00:00

  • Cysteinylation of a monoclonal antibody leads to its inactivation.

    abstract::Post-translational modifications can have a signification effect on antibody stability. A comprehensive approach is often required to best understand the underlying reasons the modification affects the antibody's potency or aggregation state. Monoclonal antibody 001 displayed significant variation in terms of potency,...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1160179

    authors: McSherry T,McSherry J,Ozaeta P,Longenecker K,Ramsay C,Fishpaugh J,Allen S

    更新日期:2016-05-01 00:00:00

  • High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface.

    abstract::Antibody engineering must be accompanied by mapping strategies focused on identifying the epitope recognized by each antibody to define its unique functional identity. High throughput fine specificity determination remains technically challenging. We review recent experiences aimed at revisiting the oldest and most ex...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.36144

    authors: Rojas G,Tundidor Y,Infante YC

    更新日期:2014-01-01 00:00:00

  • Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library.

    abstract::A costimulatory signal is required for the full activation of T cells, in addition to the antigen-specific signal via the T cell receptor. The inducible costimulator, ICOS is one of the costimulatory molecules that play an essential role in this process, particularly in the expansion or the development of effector T c...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.5.9633

    authors: Maeda M,Ito Y,Hatanaka T,Hashiguchi S,Torikai M,Nakashima T,Sugimura K

    更新日期:2009-09-01 00:00:00

  • Target-independent variable region mediated effects on antibody clearance can be FcRn independent.

    abstract::The importance of the neonatal Fc receptor (FcRn) in extending the serum half-life of monoclonal antibodies (mAbs) is well demonstrated, and has led to the development of multiple engineering approaches designed to alter Fc interactions with FcRn. Recent reports have additionally highlighted the effect of nonspecific ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1208330

    authors: Kelly RL,Yu Y,Sun T,Caffry I,Lynaugh H,Brown M,Jain T,Xu Y,Wittrup KD

    更新日期:2016-10-01 00:00:00

  • Clinical considerations for the development of biosimilars in oncology.

    abstract::Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the approval of biosimilars. The term "biosimilar" refers to a biologic product that is developed to b...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2015.1008346

    authors: Socinski MA,Curigliano G,Jacobs I,Gumbiner B,MacDonald J,Thomas D

    更新日期:2015-01-01 00:00:00

  • A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.

    abstract::A mono-specific antibody may recruit a second antigen binding specificity, thus converting to a dual-specific Two-in-One antibody through mutation at the light chain complementarity-determining regions (CDRs). It is, however, unknown whether mutation at the heavy chain CDRs may evolve such dual specificity. Herein, we...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28483

    authors: Lee CV,Koenig P,Fuh G

    更新日期:2014-05-01 00:00:00

  • Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies.

    abstract::The plasticity of natural immunoglobulin repertoires can be exploited for the generation of phage display libraries. Secondary lymphoid organs, such as the spleen and the lymph nodes, constitute interesting sources of diversity because they are rich in B cells, part of which can be affinity matured. These organs, howe...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25592

    authors: Venet S,Kosco-Vilbois M,Fischer N

    更新日期:2013-09-01 00:00:00

  • Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.

    abstract::Optimization of biophysical properties is a critical success factor for the developability of monoclonal antibodies with potential therapeutic applications. The inter-domain disulfide bond between light chain (Lc) and heavy chain (Hc) in human IgG1 lends structural support for antibody scaffold stability, optimal anti...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.24291

    authors: Shen Y,Zeng L,Zhu A,Blanc T,Patel D,Pennello A,Bari A,Ng S,Persaud K,Kang YK,Balderes P,Surguladze D,Hindi S,Zhou Q,Ludwig DL,Snavely M

    更新日期:2013-05-01 00:00:00

  • Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.

    abstract::The neonatal Fc receptor (FcRn) promotes antibody recycling through rescue from normal lysosomal degradation. The binding interaction is pH-dependent with high affinity at low pH, but not under physiological pH conditions. Here, we combined rational design and saturation mutagenesis to generate novel antibody variants...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1633883

    authors: Mackness BC,Jaworski JA,Boudanova E,Park A,Valente D,Mauriac C,Pasquier O,Schmidt T,Kabiri M,Kandira A,Radošević K,Qiu H

    更新日期:2019-10-01 00:00:00

  • Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

    abstract::The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low and many patients exp...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.6.17955

    authors: Koefoed K,Steinaa L,Søderberg JN,Kjær I,Jacobsen HJ,Meijer PJ,Haurum JS,Jensen A,Kragh M,Andersen PS,Pedersen MW

    更新日期:2011-11-01 00:00:00

  • Certolizumab pegol.

    abstract::Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pe...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.2.11271

    authors: Goel N,Stephens S

    更新日期:2010-03-01 00:00:00

  • Cell culture processes for monoclonal antibody production.

    abstract::Animal cell culture technology has advanced significantly over the last few decades and is now generally considered a reliable, robust and relatively mature technology. A range of biotherapeutics are currently synthesized using cell culture methods in large scale manufacturing facilities that produce products for both...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.5.12720

    authors: Li F,Vijayasankaran N,Shen AY,Kiss R,Amanullah A

    更新日期:2010-09-01 00:00:00

  • Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

    abstract::The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27-28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cy...

    journal_title:mAbs

    pub_type:

    doi:10.1080/19420862.2017.1412130

    authors: Martin C,Kizlik-Masson C,Pèlegrin A,Watier H,Viaud-Massuard MC,Joubert N

    更新日期:2018-02-01 00:00:00

  • Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.

    abstract::Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like molecules, designated diabody-Ig (Db-Ig). The antigen-binding site of D...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1603024

    authors: Seifert O,Rau A,Beha N,Richter F,Kontermann RE

    更新日期:2019-07-01 00:00:00

  • Sequencing antibody repertoires: the next generation.

    abstract::Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and disc...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.1.14169

    authors: Fischer N

    更新日期:2011-01-01 00:00:00

  • Discovery of high affinity anti-ricin antibodies by B cell receptor sequencing and by yeast display of combinatorial VH:VL libraries from immunized animals.

    abstract::Ricin is a toxin that could potentially be used as a bioweapon. We identified anti-ricin A chain antibodies by sequencing the antibody repertoire from immunized mice and by selecting high affinity antibodies using yeast surface display. These methods led to the isolation of multiple antibodies with high (sub-nanomolar...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1190059

    authors: Wang B,Lee CH,Johnson EL,Kluwe CA,Cunningham JC,Tanno H,Crooks RM,Georgiou G,Ellington AD

    更新日期:2016-08-01 00:00:00

  • Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

    abstract::Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25439

    authors: Challa DK,Bussmeyer U,Khan T,Montoyo HP,Bansal P,Ober RJ,Ward ES

    更新日期:2013-09-01 00:00:00

  • Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.

    abstract::The neonatal Fc receptor (FcRn) plays an important and well-known role in antibody recycling in endothelial and hematopoietic cells and thus it influences the systemic pharmacokinetics (PK) of immunoglobulin G (IgG). However, considerably less is known about FcRn's role in the metabolism of IgG within individual tissu...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28254

    authors: Yip V,Palma E,Tesar DB,Mundo EE,Bumbaca D,Torres EK,Reyes NA,Shen BQ,Fielder PJ,Prabhu S,Khawli LA,Boswell CA

    更新日期:2014-05-01 00:00:00

  • Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.

    abstract::The linear pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs) can be considered a class property with values that are similar to endogenous IgG. Knowledge of these parameters across species could be used to avoid unnecessary in vivo PK studies and to enable early PK predictions and pharmacokinetic/pharm...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1462429

    authors: Betts A,Keunecke A,van Steeg TJ,van der Graaf PH,Avery LB,Jones H,Berkhout J

    更新日期:2018-07-01 00:00:00

  • Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

    abstract::Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of thes...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1494105

    authors: Satta A,Mezzanzanica D,Caroli F,Frigerio B,Di Nicola M,Kontermann RE,Iacovelli F,Desideri A,Anichini A,Canevari S,Gianni AM,Figini M

    更新日期:2018-10-01 00:00:00

  • Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

    abstract::Immunoglobulins and T cell receptors (TCRs) share common sequences and structures. With the goal of creating novel bispecific antibodies (BsAbs), we generated chimeric molecules, denoted IgG_TCRs, where the Fv regions of several antibodies were fused to the constant domains of the α/β TCR. Replacing CH1 with Cα and CL...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1007826

    authors: Wu X,Sereno AJ,Huang F,Zhang K,Batt M,Fitchett JR,He D,Rick HL,Conner EM,Demarest SJ

    更新日期:2015-01-01 00:00:00

  • Thermodynamic and structural characterization of an antibody gel.

    abstract::Although extensively studied, protein-protein interactions remain highly elusive and are of increasing interest in drug development. We show the assembly of a monoclonal antibody, using multivalent carboxylate ions, into highly-ordered structures. While the presence and function of similar structures in vivo are not k...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.23183

    authors: Esue O,Xie AX,Kamerzell TJ,Patapoff TW

    更新日期:2013-03-01 00:00:00

  • CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

    abstract::Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchori...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1807721

    authors: Nelke J,Medler J,Weisenberger D,Beilhack A,Wajant H

    更新日期:2020-01-01 00:00:00

  • An accelerated surface-mediated stress assay of antibody instability for developability studies.

    abstract::High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and poor conformational stability, but protein aggregation remains a challenging property to predict. ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1815995

    authors: Kopp MRG,Wolf Pérez AM,Zucca MV,Capasso Palmiero U,Friedrichsen B,Lorenzen N,Arosio P

    更新日期:2020-01-01 00:00:00

  • Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest.

    abstract::While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to th...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28257

    authors: Derfus GE,Dizon-Maspat J,Broddrick JT,Velayo AC,Toschi JD,Santuray RT,Hsu SK,Winter CM,Krishnan R,Amanullah A

    更新日期:2014-05-01 00:00:00

  • Evaluating imbalances of adverse events during biosimilar development.

    abstract::Biosimilars are designed to be highly similar to approved or licensed (reference) biologics and are evaluated based on the totality of evidence from extensive analytical, nonclinical and clinical studies. As part of the stepwise approach recommended by regulatory agencies, the first step in the clinical evaluation of ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1171431

    authors: Vana AM,Freyman AW,Reich SD,Yin D,Li R,Anderson S,Jacobs IA,Zacharchuk CM,Ewesuedo R

    更新日期:2016-07-01 00:00:00

  • Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.

    abstract::Several angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway have been approved for cancer treatment. However, VEGF inhibitors alone were shown to promote tumor invasion and metastasis by increasing intratumoral hypoxia in some preclinical and clinical studies. Emerging rep...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1171432

    authors: Lee D,Kim D,Choi YB,Kang K,Sung ES,Ahn JH,Goo J,Yeom DH,Jang HS,Moon KD,Lee SH,You WK

    更新日期:2016-07-01 00:00:00

  • Galactosylation variations in marketed therapeutic antibodies.

    abstract::There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.19868

    authors: Raju TS,Jordan RE

    更新日期:2012-05-01 00:00:00